<DOC>
	<DOCNO>NCT00574691</DOCNO>
	<brief_summary>To assess safety feasibility 7F Ensure Medical Vascular Closure Devices facilitate hemostasis patient undergoing diagnostic interventional procedure .</brief_summary>
	<brief_title>ECLIPSE Feasibility Trial ( Ensure 's Vascular Closure Device Speeds Hemostasis Trial ) EU</brief_title>
	<detailed_description>Multi-center ( 6 European site ) , non-blinded , non-randomized , feasibility study 2-month enrollment period 30-day clinical follow-up . 60 patient ( plus 36 `` roll-in '' device training patient ) undergo diagnostic interventional coronary peripheral procedure utilize 7F arterial puncture common femoral artery . Patients exclude previous target artery closure closure device , recent myocardial infarction thrombolytic therapy , treatment thrombin-specific anticoagulant low molecular weight heparin , fluoroscopically visible calcium atherosclerosis ≤ 1 cm puncture site , plan target site access ≤ 30 day .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patient 18 85 year age Patient/legal representative provide write informed consent Patient schedule coronary peripheral diagnostic interventional procedure Patient able undergo emergent vascular surgery complication relate VCD necessitate surgery Patient 7F arterial puncture locate common femoral artery Target vessel lumen diameter ≥ 5 mm Patient willing able complete followup Catheterization procedure plan elective Arterial puncture femoral artery leg Prior target artery closure closure device closure manual compression ≤ 30 day prior cardiac peripheral catheterization procedure Patients history significant bleed know documented bleeding disorder , Thrombocytopenia ( &lt; 100,000 platelet count ) , Von Willebrand 's disease , anemia ( Hgb &lt; 10 g/dL , Hct &lt; 30 % ) , thrombasthenia , decrease fibrinogen ( &lt; 200 mg/dL ) , Factor V deficiency Acute STelevation myocardial infarction ≤ 48 hour prior cardiac peripheral catheterization procedure Uncontrolled hypertension ( BP ≥ 180/110 mmHg ) Heparinized patient elevated preclosure ACT level : &gt; 250 second GP IIb/IIIa inhibitor &gt; 300 second GP IIb/IIIa inhibitor Patient ineligible inlab catheterization lab introducer sheath removal Concurrent participation another investigational device drug trial Thrombolytic therapy ( e.g . streptokinase , urokinase , tPA ) ≤ 24 hour prior cardiac peripheral catheterization procedure Angiomax ( bivalirudin ) thrombinspecific anticoagulant low molecular weight heparin ≤ 24 hour prior cardiac peripheral catheterization procedure Evidence preexisting hematoma , arteriovenous fistula , pseudoaneurysm access site prior start femoral artery closure procedure Prior femoral vascular surgery vascular graft region access site contralateral common femoral artery The targeted femoral artery tortuous require introducer sheath length &gt; 11 cm Fluoroscopically visible calcium , atherosclerotic disease , stent ≤ 1 cm puncture site would interfere placement VCD 's plug Difficulty obtain vascular access result multiple arterial puncture and/or posterior arterial puncture Antegrade puncture BMI &gt; 40 kg/m2 Symptomatic leg ischemia target vessel limb include severe claudication ( &lt; 50 meter ) weak/absent pulse Targeted femoral artery diameter stenosis ≥ 50 % Preexisting severe noncardiac systemic disease preexist terminal illness Planned arterial access access site ≤ 30 day follow femoral artery closure procedure Patient know allergy material use VCD Patient know require extend hospitalization ( e.g . patient undergo CABG surgery ) Preexisting systemic cutaneous infection Prior recent use intraaortic balloon pump arterial access site Cardiogenic shock ( hemodynamic instability require intravenous medication mechanical support ) experience immediately postcatheterization Patient unable ambulate baseline Patient know suspect pregnant , lactating Patient already participate trial Patient know allergy contrast medium Patient unavailable followup Any angiographic clinical evidence investigator feel would place patient increase risk use VCD Required simultaneous ipsilateral contralateral venous puncture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Closure Device</keyword>
	<keyword>Angiography</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Heart Catheterization</keyword>
	<keyword>Coronary Angiography</keyword>
</DOC>